Literature DB >> 11157485

Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.

S W Pipe1, E L Saenko, A N Eickhorst, G Kemball-Cook, R J Kaufman.   

Abstract

Thrombin-activated factor VIII (FVIIIa) is a heterotrimer with the A2 subunit (amino acid residues 373-740) in a weak ionic interaction with the A1 and A3-C1-C2 subunits. Dissociation of the A2 subunit correlates with inactivation of FVIIIa. Patients with hemophilia A have been described whose plasmas display a discrepancy between their FVIII activities, where the 1-stage activity assay displays greater activity than the 2-stage activity assay. The molecular basis for one of these mutations, (ARG)531(HIS), is an increased rate of A2 subunit dissociation. Examination of a homology model of the A domains of FVIII predicted (ARG)531 to lie at the interface of the A1 and A2 subunits and stabilize their interaction. Indeed, patients with mutations either directly contacting (ARG)531 ((ALA)284(GLU), (ALA)284(PRO)) or closely adjacent to the A1-A2 interface in the tightly packed hydrophobic core ((SER)289(LEU)) have the same phenotype of 1-stage/2-stage discrepancy. The (ALA)284(GLU) and (SER)289(LEU) mutations in FVIII were produced by transfection of COS-1 monkey cells. Compared to FVIII wild-type both mutants had reduced specific activity by 1-stage clotting activity and at least a 2-fold lower activity by 2-stage analysis (COAMATIC), similar to the reported clinical data. Analysis of immunoaffinity purified (ALA)284(GLU) and (SER)289(LEU) proteins in an optical biosensor demonstrated that A2 dissociation was 3-fold faster for both FVIIIa mutants compared to FVIIIa wild-type. Therefore, these mutations within the A1 subunit of FVIIIa introduce a similar destabilization of the FVIIIa heterotrimer compared to the (ARG)531(HIS) mutation within the A2 subunit and support that these residues stabilize the A domain interface of FVIIIa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157485     DOI: 10.1182/blood.v97.3.685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

2.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

3.  Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the F8 gene.

Authors:  Giancarlo Castaman
Journal:  Haematologica       Date:  2018-02       Impact factor: 9.941

4.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

5.  Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A.

Authors:  Hiroshi Inaba; Keiko Shinozawa; Ikuo Seita; Manabu Otaki; Takashi Suzuki; Takeshi Hagiwara; Kagehiro Amano; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2013-04-27       Impact factor: 2.490

6.  Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

7.  Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

Authors:  H Trent Spencer; Gabriela Denning; Richard E Gautney; Boro Dropulic; Andre J Roy; Lajos Baranyi; Bagirath Gangadharan; Ernest T Parker; Pete Lollar; Christopher B Doering
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

8.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

9.  Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

Authors:  M Monaghan; H Wakabayashi; A Griffiths; J Wintermute; P J Fay
Journal:  Thromb Haemost       Date:  2014-06-05       Impact factor: 5.249

10.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.